A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid

Author:

Kaniga Koné1,Cirillo Daniela M.2,Hoffner Sven3,Ismail Nazir A.45,Kaur Devinder6,Lounis Nacer7,Metchock Beverly8,Pfyffer Gaby E.9,Venter Amour10

Affiliation:

1. Janssen Research & Development, LLC, Titusville, New Jersey, USA

2. IRCCS, San Raffaele Scientific Institute, Milan, Italy

3. TB Supranational Reference Laboratory, The Public Health Agency of Sweden, Solna, Sweden

4. National TB Reference Laboratory, Center for Tuberculosis, National Institute of Communicable Diseases, Johannesburg, South Africa

5. Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa

6. University of Massachusetts Medical School, Massachusetts Supranational TB Reference Laboratory, Boston, Massachusetts, USA

7. Janssen Pharmaceutica NV, Beerse, Belgium

8. Reference Laboratory, Division of TB Elimination, United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA

9. Department of Medical Microbiology, Center of Laboratory Medicine, Luzerner Kantonsspital LUKS, Luzern, Switzerland

10. TASK Applied Science, SA MRC Centre for TB Research, DST/NRF Center of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa

Abstract

ABSTRACT Our objective was to establish reference MIC quality control (QC) ranges for drug susceptibility testing of antimycobacterials, including first-line agents, second-line injectables, fluoroquinolones, and World Health Organization category 5 drugs for multidrug-resistant tuberculosis using a 7H9 broth microdilution MIC method. A tier-2 reproducibility study was conducted in eight participating laboratories using Clinical Laboratory and Standards Institute (CLSI) guidelines. Three lots of custom-made frozen 96-well polystyrene microtiter plates were used and prepared with 2× prediluted drugs in 7H9 broth-oleic acid albumin dextrose catalase. The QC reference strain was Mycobacterium tuberculosis H37Rv. MIC frequency, mode, and geometric mean were calculated for each drug. QC ranges were derived based on predefined, strict CLSI criteria. Any data lying outside CLSI criteria resulted in exclusion of the entire laboratory data set. Data from one laboratory were excluded due to higher MIC values than other laboratories. QC ranges were established for 11 drugs: isoniazid (0.03 to 0.12 μg/ml), rifampin (0.03 to 0.25 μg/ml), ethambutol (0.25 to 2 μg/ml), levofloxacin (0.12 to 1 μg/ml), moxifloxacin (0.06 to 0.5 μg/ml), ofloxacin (0.25 to 2 μg/ml), amikacin (0.25 to 2 μg/ml), kanamycin (0.25 to 2 μg/ml), capreomycin (0.5 to 4 μg/ml), linezolid (0.25 to 2 μg/ml), and clofazimine (0.03 to 0.25 μg/ml). QC ranges could not be established for nicotinamide (pyrazinamide surrogate), prothionamide, or ethionamide, which were assay nonperformers. Using strict CLSI criteria, QC ranges against the M. tuberculosis H37Rv reference strain were established for the majority of commonly used antituberculosis drugs, with a convenient 7H9 broth microdilution MIC method suitable for use in resource-limited settings.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Reference21 articles.

1. WHO. 2015. Global tuberculosis report 2015. WHO Geneva Switzerland. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1.

2. WHO. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO Geneva Switzerland. http://apps.who.int/iris/bitstream/10665/70500/1/WHO_HTM_TB_2008.392_eng.pdf?ua=1&ua=1.

3. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.

4. U.S. Department of Health and Human Services, Food and Drug Administration. 2009. Guidance for industry: microbiological data for systematic antibacterial drug products–development, analysis, and presentation. U.S. FDA, Washington, DC. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm182288.pdf.

5. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3